Uppsala University in European initiative for new antibiotics
Uppsala University is taking a leading role in COMBINE, a multinational collaboration where 11 partners from academia and the private sector are working together to chart new approaches for the more effective development of antibiotics.
With a central position in the new European collaboration COMBINE, Uppsala University is expanding its already strong commitment in speeding the development of new antibiotics. Innovative Medicines Initiative (IMI) – a partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA) – is behind this 25-million-euro initiative. Anders Karlén, professor of computational medicinal chemistry, is the project's coordinator.
Uppsala University also has a leading role in designing a standardised, preclinical reference model for developing antibiotics. This task includes formulating recommendations for interpreting results and guidance in how these results can predict the outcome of clinical studies.
With COMBINE’s combined process support and project support, IMI is improving the potential for achieving the ambitious goals of the ongoing billion kronor initiative Antimicrobial Resistance Accelerator Programme to develop new preclinical pharmaceutical candidates, of which five are to be ready for phase 2 studies within six year. This is an initiative that is even more important considering the approaching end of ENABLE, another IMI-financed European programme where Uppsala University is leading development of potential antibiotics against gram-negative bacteria.